Rilutek is a drug owned by Covis Pharma Gmbh. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 18, 2013. Details of Rilutek's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5527814 | Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis |
Jun, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Rilutek is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rilutek's family patents as well as insights into ongoing legal events on those patents.
Rilutek's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rilutek's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 18, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rilutek Generic API suppliers:
Riluzole is the generic name for the brand Rilutek. 8 different companies have already filed for the generic of Rilutek, with Alkem Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Rilutek's generic
Alternative Brands for Rilutek
There are several other brand drugs using the same active ingredient (Riluzole) as Rilutek. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Aquestive |
| |
| Italfarmaco Sa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Riluzole, Rilutek's active ingredient. Check the complete list of approved generic manufacturers for Rilutek
About Rilutek
Rilutek is a drug owned by Covis Pharma Gmbh. Rilutek uses Riluzole as an active ingredient. Rilutek was launched by Covis in 1995.
Approval Date:
Rilutek was approved by FDA for market use on 12 December, 1995.
Active Ingredient:
Rilutek uses Riluzole as the active ingredient. Check out other Drugs and Companies using Riluzole ingredient
Dosage:
Rilutek is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG | TABLET | Discontinued | ORAL |